Meeting
2020 ASCO Virtual Scientific Program
SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
Authors
Sujana Movva
Fox Chase Cancer Center, Philadelphia, PA
Sujana Movva , Margaret von Mehren , Elizabeth A. Handorf , Jeffrey A. Morgan , Michael Nathenson , Katherine Anne Thornton , Eric Daniel Tetzlaff , Emma Barker , Linda Thibodeau , Allisa Cherae Harley , April King , Rosanna Veggeberg , Juliet A. Leshner , Lori Rink , Suzanne George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Clinical Trial Registration Number
NCT03114527
Citation
J Clin Oncol 38: 2020 (suppl; abstr 11544)
DOI
10.1200/JCO.2020.38.15_suppl.11544
Abstract #
11544
Poster Bd #
432
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
First Author: Margaret von Mehren
Poster
2023 ASCO Annual Meeting
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
First Author: Sandra P. D'Angelo
Poster
2018 ASCO Annual Meeting
A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.
First Author: Benjamin Adam Weinberg
Poster
2013 ASCO Annual Meeting
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma.
First Author: Mark Andrew Dickson